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Background: Controlled human malaria infection (CHMI) studies, in which healthy volunteers are infected with
Plasmodium falciparum to assess the efficacy of novel malaria vaccines and drugs, have become a vital tool to
accelerate vaccine and drug development. CHMI studies provide a cost-effective and expeditious way to circumvent
the use of large-scale field efficacy studies to deselect intervention candidates. However, to date few modern CHMI
studies have been performed in malaria-endemic countries.
Methods: An open-label, randomized pilot CHMI study was conducted using aseptic, purified, cryopreserved, infectious
P. falciparum sporozoites (SPZ) (Sanaria® PfSPZ Challenge) administered intramuscularly (IM) to healthy Kenyan adults
(n = 28) with varying degrees of prior exposure to P. falciparum. The purpose of the study was to establish the
PfSPZ Challenge CHMI model in a Kenyan setting with the aim of increasing the international capacity for efficacy
testing of malaria vaccines and drugs, and allowing earlier assessment of efficacy in a population for which interventions
are being developed. This was part of the EDCTP-funded capacity development of the CHMI platform in Africa.
Discussion: This paper discusses in detail lessons learnt from conducting the first CHMI study in Kenya. Issues
pertinent to the African setting, including community sensitization, consent and recruitment are considered. Detailed
reasoning regarding the study design (for example, dose and route of administration of PfSPZ Challenge, criteria
for grouping volunteers according to prior exposure to malaria and duration of follow-up post CHMI) are given
and changes other centres may want to consider for future studies are suggested.
Conclusions: Performing CHMI studies in an African setting presents unique but surmountable challenges and
offers great opportunity for acceleration of malaria vaccine and drug development. The reflections in this paper
aim to aid other centres and partners intending to use the CHMI model in Africa.
Keywords: CHMI, Kenya, Challenge, PfSPZ Challenge, Lessons, Plasmodium falciparum, Vaccine, Drug, African,
Malaria* Correspondence: Susanne.hodgson@ndm.ox.ac.uk
1The Jenner Institute, University of Oxford, Oxford, UK
Full list of author information is available at the end of the article
© 2015 Hodgson et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Hodgson et al. Malaria Journal  (2015) 14:182 Page 2 of 12Background
Controlled human malaria infection (CHMI) studies, in
which healthy volunteers are infected with Plasmodium
falciparum to assess the efficacy of novel malaria vaccines
and drugs, have become a vital tool to accelerate vaccine
and drug development [1-5]. CHMI studies in malaria-
naïve volunteers have been shown to accurately predict
vaccine efficacy in the target African paediatric population
[6] and provide a cost-effective and expeditious way to
circumvent the use of large-scale field efficacy studies to
deselect intervention candidates [7,8].
Conducting CHMI trials in malaria-endemic rather
than ‘northern’ malaria-naïve countries has a number of
key advantages. As well as allowing early assessment of
vaccine efficacy in a population with the same genetic
background as the eventual target population, there is
the opportunity to assess the effect of prior exposure to
malaria, and the immunological priming this provides,
on vaccine efficacy [8]. Conducting CHMI trials is also
important in building the capacity of African research
institutions to become involved in the earlier stages of
vaccine or drug development. However, to date, CHMI
trials have rarely been conducted in malaria-endemic
regions, primarily because of the lack of access to the
appropriate parasite culture and insectary facilities ne-
cessary for mosquito-bite CHMI studies [1,6,8].
The development of aseptic, purified, cryopreserved,
infectious P. falciparum sporozoites (SPZ) for injection
(Sanaria® PfSPZ Challenge) has helped overcome this
problem [9]. PfSPZ Challenge is stored in liquid-
nitrogen-vapour-phase at known concentrations and as
such can be easily transported to sites, allowing admin-
istration of a known, predefined number of SPZ, and
reduction in trial-to-trial and site-to-site variation in
infecting dose [10,11].
To date, three CHMI trials using PfSPZ Challenge
have been conducted in malaria-endemic regions: the
first in Tanzania [12], the second in Kenya [13] and the
third in Gabon (Lell et al., unpublished)., This paper
provides a discussion of the experiences and lessons
learnt conducting the first CHMI study in Kenya which
should be useful given the potential future importance
of the African CHMI platform, planned African CHMI
studies at new sites (SLH, pers comm) and the unique
challenges faced when performing CHMI studies in the
developing world.
Methods
An open-label, randomized, pilot CHMI study was con-
ducted using PfSPZ Challenge administered intramuscu-
larly (IM) to healthy Kenyan adults (n = 28) with varying
degrees of prior natural exposure (Figure 1) [13]. The
purpose of the study was to establish and assess feasibility
of the PfSPZ CHMI model in a Kenyan setting with theaim of increasing the international capacity for efficacy
testing of malaria vaccines and drugs, and allowing earlier
assessment of efficacy in a population for which vaccines
or drugs are being developed.
The study was conducted at the KEMRI Centre for
Clinical Research, Nairobi, Kenya according to the prin-
ciples of the Declaration of Helsinki, in accordance with
Good Clinical Practice and in line with WHO guidelines
on the conduct of sporozoite CHMI studies [14]. The
study was registered with the Pan African Clinical Trial
Registry (PACTR20121100033272) and conducted in
accordance with an Investigational New Drug (IND) appli-
cation filed with the US Food and Drug Administration
FDA (IND 14267).
Inclusion and exclusion criteria for the study are
shown in Additional file 1: Table S1. At screening, in
addition to a full medical history, physical examination,
urinalysis and pregnancy test in females, safety blood
tests (including complete blood count, haemoglobin-
opathy screen, electrolytes, liver function tests and assays
for HIV, hepatitis B, hepatitis C), and an electrocardiogram
were performed for each volunteer to identify and exclude
any individuals with baseline abnormalities [15,16]. Highly
sensitive qPCR for P. falciparum was performed on
screening blood samples to identify and exclude any indi-
viduals with asymptomatic parasitaemia. Volunteers
positive for P. falciparum by qPCR at screening were
treated with a therapeutic course of artemether/lume-
fantrine (Co-Artem®) as per national guidelines. All
volunteers were asked not to leave Nairobi in the four
weeks between screening and enrolment in order to
prevent any community-acquired P. falciparum infec-
tion prior to CHMI. Volunteers with clinically signifi-
cant illness at screening were excluded and referred for
appropriate management as per national guidelines.
All volunteers were managed in an in-patient setting
from the day before administration of PfSPZ Challenge
(C-1) until completion of anti-malarial therapy (max-
imum 23 days post administration of PfSPZ Challenge).
All volunteers were successfully infected with P. falcip-
arum as confirmed by qPCR. All but one volunteer (110)
became blood-film positive prior to day 21 post injection
of PfSPZ Challenge (C+21). All volunteers completed
anti-malarial therapy and follow-up as scheduled. Adverse
events (AEs) associated with clinical malaria infection
were broadly similar to those observed in ‘northern’
clinical trials centres [13,17,18].
Discussion
Consultation
A detailed plan for community sensitization for the
study was drawn up in advance of the study (Table 1).
Four years before the start of the trial, consultations began
with key stakeholders in Kenya see below. At these
Figure 1 Study design and volunteer recruitment. 118 participants were excluded following screening. For reasons see Figure 2. In each group,
the total dose of sporozoites was split between two injection sites and administered as two 50 μL injections, one in each deltoid.
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scientific issues were discussed. All parties supported the
establishment of a CHMI centre in Kenya as a key object-
ive in line with national and regional research priorities. A
decision was made for Nairobi to be the preferred site for
the first CHMI study, given the ease of access to tertiary
medical centres, the relative lack of natural malaria trans-
mission and large concentration of educated individuals
best placed to provide informed consent. Initial discus-
sions focused on developing an insectary capable of sup-
porting mosquitoes imported from abroad for mosquito-
bite CHMI studies [1]. However, when PfSPZ Challenge
became available, this option was chosen due to its prac-
tical advantages [9].
Kenyan stakeholders consulted in advance of submis-
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Detailed discussion with key stakeholders years ahead
of the planned study was an important two-way
process, increasing understanding and acceptance of
the CHMI model in key national stakeholders and
allowing important feedback to guide the study design
and increase speed of ethical and regulatory approvals
at a later date.
Ethical and regulatory approvals
Kenya has a multi-tiered system of human subjects
research review where proposals go through three
or more rounds of review prior to approval. Follow-
ing review by the KEMRI Kilifi Centre Scientific
Committee (CSC) and the KEMRI Centre for Clinical
Research CSC, the study was reviewed by the national
KEMRI Scientific Steering Committee (SSC) and then
later approved by the KEMRI Ethics Review Committee
(ERC). The ERC requested additional information
regarding access to intensive care facilities, the ra-
tionale for the proposed amount of monetary com-
pensation (see Consent) and a clear description of
how the target population of educated adults would be
approached. Final ethical approval to conduct the
study was received six months after initial submission
to the CSC.
The University of Oxford requires ethical approval
from the Oxford Tropical Research Ethics Committee
(OXTREC) for all clinical trials it sponsors overseas.
Prior to approval, OXTREC requested justification
for the proposed amount of monetary compensa-
tion, clarification on consent processes for long-term
storage of samples and subsequent assays on these
samples and assurances regarding the sensitivity of
PfSPZ Challenge to the proposed anti-malarial therapy.
Ethics approval from OXTREC took two months from
initial submission.
Prior to regulatory approval, the Kenyan Pharmacy
and Poisons Board requested assurances as to how
PfSPZ Challenge would be transported and stored at
-140°C. Regulatory approval took three weeks from ini-
tial submission. An import permit was granted for PfSPZ
Challenge and the two required diluents for injection
(25% human albumin solution and phosphate buffered
saline), which were imported from the USA. A test ship-
ment labelled as PfSPZ Challenge and diluents passed
through Customs with no delays. PfSPZ Challenge is
subject to an Investigational New Drug Application filed
with the FDA and sponsored by its manufacturer, Sanaria
Inc. In this capacity the FDA reviewed and approved
the study.
Just prior to the start of screening, the international
CHMI community was made aware of a second cardiac
serious AE occurring in a mosquito-bite CHMI studyassessing a malaria vaccine at Radboud University
Medical Centre, Nijmegen, The Netherlands [16]. The
study protocol and consent form was updated to reflect
this new information and add an electrocardiogram
(ECG) to the investigations performed on all individuals
undergoing screening. Approval was sought for these
amendments from the relevant ethical and regulatory
authorities. All approvals were obtained within 37 days
of the applications, allowing the study to go ahead
according to the original timelines.Conclusion
All bodies were supportive of the study and recognized
its importance. The initial multistage approval process
did take a considerable time but ensured the study was
rigorously reviewed. Given that the dates of the CHMI
aspect of study were required to be set well in advance
(see Study design), the swift approval of the substantial
amendment was extremely important as it allowed the
study to proceed on schedule with appropriate updated
information for volunteers.Community sensitization
All community sensitization occurred following ap-
proval of the study and at a local, rather than national
level. Therefore, feedback gained from the community
will be used to inform the design of future CHMI
studies. Given the novel and complex study nature
of the study, [19] community sensitization focused
on local medical schools as it was felt this popula-
tion were most likely to have some existing under-
standing of the concept of research. Letters were
sent to the heads of the three main medical schools
in Nairobi, requesting permission to present the
study to staff and students. This occurred at three
meetings which took place approximately six weeks
before the start of screening, and took the form of
a formal presentation by the Principal Investigator
on the background and purpose of CHMI studies,
followed by details of the planned study. Approxi-
mately 200 individuals in total attended these meet-
ings. The list of questions raised at the meetings
and the reasons attendees gave to participate or not
in the study are shown below. About half of individ-
uals at the meetings said they would consider par-
ticipating in the study. Posters advertising the trial
were placed at the medical schools and interested
individuals were asked to contact the study team to
attend an individual information meeting and receive
the volunteer information sheet (VIS; see Additional
file 1). Two-hundred and forty-three individuals sub-
sequently received the VIS and 146 attended for
screening visits at a later date.
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Questions Addressed in the VIS:
– Does one have to stay in hospital throughout the study?
– What is the compensation that will be given?
– What are the risks of participating?
– If it happens that I do not react as expected, what
will happen?
– The method of injection is new - is it safe?
– How do you compare mosquito and injection?
– What will make you choose me to participate in the
study?
– Will I be subjected to pricking (blood sampling)?
– What if I have commitments at the time of the study?
– In brief, what message can I give my friends about
this study?
– How many people will participate?
– What are your expectations?
– I know my parents will want to know – are there
other people involved in the study other than students
say for example a doctor or just other people?
– What if I react on day 1?
– With the dates of the study procedures you have
given it seems this might interfere with our studies
and we all know our education should come first.
What do you have to say about this?
– What are the benefits of participation in this study?
– Is there risk of infection?
– Now that we are going to take part in the study who
will do the research, KEMRI or the students?
– How much of our time do you need for the study?
Questions not Addressed in the VIS:
– Where can I get more information about this product?
– Will you be involving only people from Nairobi or
also outside Nairobi?
– Do you just sit down the whole day doing nothing?
– Is visiting allowed?
– Will there be a document to say I have participated
in this study, like a certificate or a letter saying I was
involved?
Reasons given at community sensitization meetings
to participate or decline to participate in the study
Reasons given to participate
– I am patriotic and I would love to take part in this
study to help my country.
– One day I will have my own family and by my
participation in this particular study I will be helping
to generate very important medical knowledge that
will one day help my own children and other
families in Kenya.– For curiosity.
– I would have been happy to volunteer in the malaria
vaccine study (RTS,S) if given the opportunity as I
have seen it has generated very useful data.
Reasons given not to participate
– I am scared of my parents’ reaction.
– I will be having job interviews during the time.
– I am scared of needles.
– Staying away for that long and being unable to do
my things.
– It is a new thing – we do not know what to expect.
Conclusion
Meetings at the medical schools provided an excellent
forum to explain the study to a target, educated audi-
ence with a prior understanding of the concept of
research and discuss and explain all aspects of the study.
The VIS of future studies will be updated to address
those questions raised at community sensitisation meet-
ings that were not addressed in the VIS.
Consent
Informed consent
At screening, at least 24 hours after individuals received
the VIS, volunteers discussed the study in detail in a
one-on-one setting with Kenyan study investigators who
were also physicians. All volunteers who presented for
screening were happy to consent to participate in the
study. Prior to obtaining written consent, all volunteers
were required to undertake a written questionnaire to
assess their understanding of the study (Additional file
1). Volunteers were required to answer all questions cor-
rectly before being allowed to consent to the study and
were only allowed to attempt the questionnaire a max-
imum of three times. After each attempt, the participant
was allowed to ask for clarification of any points from
the study investigator. Of the 146 screened volunteers,
100% required at least two attempts and 55% required
three attempts to correctly answer all questions on the
questionnaire. Volunteers completed two written con-
sent forms: one to participate in the study and one to
allow the long-term storage of samples taken during the
course of the study.
To meet inclusion criteria, all volunteers were required
to provide evidence of completion of secondary educa-
tion (typically completed at age 16-18 years). It was
anticipated that participants would have some under-
standing of the concept of research and might raise
different questions and concerns to participants in studies
conducted at field sites. It was emphasised that in contrast
to many studies, this study would involve making healthy
individuals unwell (for a short while). Key concerns
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discussed in screening appointments, namely: concern
that the trial was ‘high risk’, the volume of blood taken and
the need for an extended in-patient stay (Table 2).
Compensation for study participation
Volunteers were offered financial compensation for trans-
port expenses and time away from potential income gen-
eration or actual work in order to participate in the study.
Based on local wages and comparison with the Tanzanian
CHMI study initiated in March 2012 [12], this was $50
(Kshs 4,000) for each overnight stay, $12 (Kshs 1,000) for
each scheduled clinic visit, and $6 (Kshs 500) for each
return journey to clinic. The ERC and OXTREC agreed
that these amounts would neither unduly coerce potential
participants nor set a difficult precedent for other research
conducted within the programme. The availability of
financial compensation for enrolled volunteers but not the
amount was disclosed at the community sensitization
meetings. Only volunteers receiving the VIS at laterTable 2 Questions raised by volunteers at screening
appointments




Effects of malaria infection and
treatment: short and long-term
27 16%
Details of in-patient stay and
travel out of Nairobi
20 12%
Availability of test results 19 11%
Blood sampling 13 8%
Further explanation of study
logistics
13 8%
Parasite strain used in CHMI 13 8%
Prior studies of PfSPZ Challenge 10 6%
Rationale for allocation to
groups
9 5%
Malaria treatment 7 4%
Study start date 7 4%
Compensation 6 4%
Post CHMI follow-up 5 3%
Purpose of the research 4 2%
Possibility of failure of infection 3 2%
Criteria for malaria treatment 3 2%
Failure to cure malaria infection 2 1%
Injection sites of PfSPZ
Challenge
2 1%
Proof of participation in the
study
2 1%
Resistance of PfSPZ Challenge
to anti-Malarial drugs
2 1%information meetings were aware of the amount paid as
compensation for participation in the study.
Conclusion
The informed consent questionnaire was a valuable tool
to identify areas where volunteers’ understanding was
lacking and facilitate focused discussion with the study
investigators. However, the fact all volunteers had to take
the questionnaire at least two times suggests volunteers
had difficulty understanding the complex study. To rect-
ify this in the future, the length of the information meet-
ings will be extended to allow even more detailed
discussion of the study details. The wide range and so-
phistication of questions asked both at screening and at
the community sensitization meetings was a reassuring
indication that individuals were engaging with the study.
The financial compensation offered to participants did
not appear to unduly influence volunteers’ decisions to
participate in the study as supported by the fact of the
243 individuals receiving the VIS only 146 attended for
screening.
Recruitment and target population
The occupations of screened volunteers are shown in
Additional file 1: Table S2. Despite only promoting the
study in medical schools, only 54% of screened volun-
teers were students, suggesting dissemination of news of
the study beyond the planned advertising targets.
As the first CHMI study undertaken in Kenya, the
exclusion criteria were extensive (Additional file 1:
Table S1) and only 45/146 (31%) of the screened volun-
teers were eligible to participate in the study (Figure 2).
Key factors were the high degree of previously undiag-
nosed co-morbidities and haemoglobinopathies.
Haemoglobinopathies
Given the known, significant protective effect of sickle
cell trait and both heterozygous and homozygous α-
thalassaemia against severe malaria [20,21], volunteers
with these conditions were screened and excluded from
the study. This did however markedly reduce the pro-
portion of eligible volunteers. As these haemoglobino-
pathies only confer mild or no protection against mild
malaria and asymptomatic parasitaemia [20], future
CHMI studies could consider including such volunteers.
Indeed, in the recent Tanzanian CHMI study using
PfSPZ Challenge, a considerable number of enrolled
volunteers were heterozygous for α-thalassaemia and no
evidence of an effect on parasite growth dynamics
(PGD) was seen post CHMI [12]. An added advantage
of including volunteers with these haemoglobinopathies
in future CHMI studies is the ability to assess the effi-
cacy of novel vaccines and drugs in participants more
representative of the target population at large.
Figure 2 Primary reasons for exclusion of volunteers. Of some individuals met multiple exclusion criteria. This figure illustrates the primary reason
for exclusion for each volunteer. ‘HIV’ = human immunodeficiency virus; ‘ECG’ = electrocardiogram; ‘PCR’ = polymerase chain reaction for P. falciparum;
‘ALT’ = Alanine transaminase; ‘Homo α thal’ = Homozygous α thalassemia; ‘Hetero α thal’ = Heterozygous α thalassemia; βHCG = β Human
Chorionic Gonadotropin.
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One of the aims of the study was to assess PGD in
volunteers with varying degrees of prior exposure, and
therefore presumed naturally acquired immunity (NAI)
to P. falciparum [22]. Although there is little or no nat-
ural transmission of malaria in Nairobi [23], the study
team were confident of the ability to recruit volunteers
with varying degrees of prior exposure to P. falciparum
given the highly migratory nature of the population of
Nairobi.
Volunteers were to be divided into two main cohorts:
individuals with evidence of marked prior exposure (i.e.,
semi-immune; Groups 2, 4 and 6) and individuals with
no evidence of prior exposure to P. falciparum (Groups
1, 3 and 5) (Figure 1). Given the lack of a known assay
to reliably assess NAI [22], serological and historical
geographical data were to be used as criteria for grading
prior exposure to P. falciparum, as a surrogate measure
of NAI (Table 3). Data were collected at screening re-
garding volunteers’ place of birth, location of schoolingand higher education and time spent in Nairobi directly
prior to screening. Serologically, two key antigens were
chosen on the basis of their published, positive associ-
ation with prior exposure to P. falciparum: total schizont
antigens and merozoite surface protein 2 (MSP2) [24-28].
Absolute ELISA OD results to these two antigens for
screening samples were compared to negative controls
(non-exposed UK sera; n = 30) and the cut-off for sero-
positivity determined as the mean absolute ELISA OD
plus three standard deviations of the negative controls
(0.23 and 0.07 for reactivity against schizont extract and
MSP2, respectively).
Following collection of data from screening, it became
clear the initial criteria for classifying volunteers were
unworkable. Firstly, in the target, educated population,
most had attended boarding schools and higher edu-
cation institutions at multiple locations, considerable
distances from their place of birth, making it extremely
difficult to quantify time spent in malaria-endemic
regions (Additional file 1: Tables S3 and S4). Secondly,







Time spent in endemic region
1, 3, 5 None All negative None Lived whole life in Nairobi or similar area where P. falciparum is not endemic.
2, 4, 6 Maximal High positive +/- Vast majority of life spent in western Kenya in area of high P. falciparum
transmission. Immediately prior to CHMI, should not have spent more than
6 months out of endemic region.
*Anti-Pf serology = Anti-schizont and Anti-MSP2 antibodies.
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arum… present in all areas (including game parks) (of
Kenya) at altitudes below 2,500 m (8,202ft) with none in
the highly urbanized, central part of the city of Nairobi”)
[23], nearly all volunteers had spent significant time in a
malaria-endemic region (Additional file 1: Tables S3
and S4). Although information on volunteers’ reported
history of episodes of blood smear-confirmed malaria
infections was collected, it was impossible to validate
these reports, since many individuals had taken anti-
malarial medications for presumed malaria infection
unconfirmed by blood smear and it was difficult to ac-
cess medical records retrospectively.
On review, it was felt serological data were the most
objective measure to assess prior exposure to P. falcip-
arum. Given that anti-schizont OD results reflect reacto-
genicity to multiple antigens in parallel, it was decided
to use this assay as the primary serological endpoint.
Individuals were, therefore, redefined into those with
evidence of minimal prior exposure (MinExp: Groups 1,
3 and 5) and those with definite evidence of prior ex-
posure (DefExp: Groups 2, 4 and 6) on the basis of
serological data alone (Table 4). In the final enrolled
volunteers, it was ensured that the geographical history
was consistent with the serological data (for example,
that volunteers reporting lifelong residence in Nairobi
were not in the DefExp group).
On analysis of data, only five screened individuals had
anti-schizont OD readings of the same order as ‘hyper-
immune’ controls (Figure 3) and due to a high degree of
previously undiagnosed co-morbidities in these five indi-
viduals, only one of these volunteers was subsequently
eligible to participate in the study. In practice therefore,
the eligible volunteer pool was made up of subjects with
varying but probably nil to mild/moderate prior





1, 3, 5 Minimal All negative
2, 4, 6 Definite Positive anti-schizont +/-
anti-MSP2
*Anti-Pf serology = Anti-schizont and Anti-MSP2 antibodies.Asymptomatic parasitaemia at screening
Whilst malaria transmission is minimal in Nairobi [23],
it was important to ensure volunteers were not para-
sitaemic with naturally acquired P. falciparum prior to
administration of PfSPZ Challenge. Administration of a
course of curative anti-malarials to all enrolled volun-
teers prior to CHMI was considered, however, there
were concerns that even a medication with a reported
short half-life could impact on PfSPZ Challenge infectiv-
ity or PGD [29]. Instead, all volunteers qPCR-positive
for P. falciparum at screening were excluded (Additional
file 1: Table S1). Seven volunteers (5%) were excluded
using this criterion (Figure 2). All were asymptomatic:
five with a ‘low positive’ unquantifiable result (below the
lower limit of quantification for the assay: 20 parasites/
mL) and two with quantifiable results of 55 and 669 par-
asites/mL. These seven volunteers were treated with a
course of anti-malarial therapy according to national
guidelines and excluded from the study. Whilst it is
unclear when these individuals were infected with malaria,
they may have been semi-immune volunteers capable of
controlling parasitaemia; indeed 4/7 (57%) met the criteria
for DefExp. Given the difficulty recruiting such individuals
in Nairobi, it was an unfortunate effect of the study design
that it was necessary to exclude such volunteers.
Conclusion
Given only 54% of screened volunteers were students, it
was felt that there was no clear advantage to exclusively
targeting medical students and future studies would
appeal to students of all disciplines.
Exclusion of volunteers heterozygous for α-thalassaemia
markedly limited recruitment and future CHMI studies
should consider inclusion of such volunteers. Grouping
volunteers according to prior exposure to malaria, and
therefore NAI was extremely difficult given the lack of ae of prior exposure to Plasmodium falciparum
Secondary criterion:
Time spent in endemic region
Lived majority of life in Nairobi or area where
P. falciparum is not endemic.































































Figure 3 Anti-schizont antibody ELISA absolute OD readings measured
at screening. Serum diluted 1:1,000. Negative controls = OD readings
from UK malaria-naïve adults (n = 30). Positive controls = OD readings
from hyperimmune Kenyan adults living in malaria-endemic regions
(n = 6). Minimal exposure = subjects enrolled in Groups 1, 3 and 5
(n = 14). Definite exposure = subjects enrolled in Groups 2, 4 and 6
(n = 14). Screened subjects = all volunteers that had blood drawn at
screening (n = 145). Median values represented by lines through
each dataset.
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exposure on the basis of geographical data. This was com-
pounded by the highly migratory nature of the screened
population and high degree of undiagnosed co-morbid-
ities. If future Kenyan CHMI studies seek to enrol ‘hyper-
immune’ adults, it will be important to either screen a
considerably larger sample of individuals, do more tar-
geted screening or move the study site to an endemic
region. Whilst prescreening of volunteers to create a data-
base of appropriate individuals in advance of a CHMI
study could be useful logistically, given the unknown dy-
namics of the loss of NAI, such volunteers would require
rescreening ahead of enrolment to ensure accurate, timely
data immediately prior to CHMI.
Study design
Dose of PfSPZ challenge
Limited evidence existed at the time of study design to
guide the choice of dose and route of administration of
PfSPZ Challenge for this study. The dose needed to be
large enough to ensure successful infection of all volun-
teers, but not so large as to overwhelm and prevent the
ability of any NAI to control blood-stage growth in vivo.
Published clinical data at the time of the study design
showed IM administration of PfSPZ Challenge to be the
only route proven to infect 100% of volunteers [11]. How-
ever, the maximum dose used in this study (25,000 PfSPZ)
resulted in a notably lower liver-to-blood-inoculum (LBI)
than that seen in traditional mosquito-bite CHMIstudies [11,18]. In order to ensure infection and detect-
able parasitaemia post-CHMI, a higher dose of 125,000
PfSPZ IM was chosen for the main study cohort (n = 20).
Since this would be the largest dose of PfSPZ Challenge
administered IM to humans at the time [11], two
additional, small, lead-in cohorts receiving lower doses
of 25,000 (n = 4) and 75,000 (n = 4) PfSPZ IM were in-
cluded in the study design.
Reassuringly, a similar safety profile to that reported in
malaria-naïve subjects who underwent CHMI was seen,
with the exception that Kenyan participants experienced
AEs of a notably longer duration than malaria-naïve
volunteers, the reason for which is unclear [13].
Schedule of enrolment
In order to minimize vials of PfSPZ Challenge used and
ensure standardization with other PFSPZ Challenge stud-
ies, staff from Sanaria Inc USA prepared and dispensed
syringes of PfSPZ Challenge, which were required to be ad-
ministered within 30 minutes of thawing of PfSPZ Chal-
lenge. For logistical reasons it was decided all volunteers
would undergo CHMI in the same week. Given a safety
review by the Safety Monitoring Committee (SMC) was re-
quired prior to each dose escalation of PfSPZ Challenge,
safety data had to be compiled in real-time and SMC
members briefed in advance to allow a strict schedule of
reviews prior to approval of each dose escalation to be met
(Additional file 1: Table S5). The fact that all volunteers
were enrolled in one week meant that the phase of in-
patient follow-up lasted just 28 days and so intensive nurs-
ing and laboratory support was only required for a month.
In-patient setting
Depending on the setting, management of subjects
undergoing CHMI is done on an patient or out-patient
basis [14]. Given the need to prioritize volunteer safety
in this pilot study, the fact that considerable traffic con-
gestion in Nairobi could seriously impede volunteers’
ability to attend the medical centre in a timely fashion
and the lack of ease of access to public health care,
it was decided that volunteers would be managed as
in-patients from the day before injection of PfSPZ
Challenge until completion of anti-malarial therapy. The
need for in-patient care was emphasized to participants
at screening and again prior to enrolment. Clear proto-
cols were established and explained to both staff and
participants regarding the actions to be taken if a partici-
pant were to go missing [30]. Participants were encour-
aged to voice any concerns they had about their living
conditions, treatment or change in personal circum-
stances early so that issues could be addressed quickly
and anti-malarial treatment initiated in a timely fashion
if a volunteer wished to withdraw from the study and
leave the in-patient clinic.
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As the first pilot study in Kenya, a follow-up schedule
similar to European centres was adopted, with all un-
diagnosed participants treated at C+21 [14]. One par-
ticipant (110) who had an anti-schizont ELISA OD at
screening similar to hyperimmune individuals was
qPCR-positive but blood film-negative (and therefore
undiagnosed) on C+21 (Figure 4). It would be ex-
tremely interesting to examine the PGD of this, and
other hyperimmune individuals if a longer window of
follow-up prior to treatment of undiagnosed partici-
pants were adopted. One benefit could be the ability to
track the development of gametocytaemia. In this
study, no qPCR specific for gametocytes was per-
formed, and so it is possible that the rise in qPCR seen
in participant 110 from C+19 onwards reflected game-
tocytaemia rather than loss of control of the blood
stage of infection. In future studies, if qPCR specific for
gametocytes were performed and a phenotype of indi-
viduals identified that were able to control blood-stage
infection, remain asymptomatic but develop gameto-
cytes, this could allow for the development of a much
needed clinical model to assess the efficacy of novel
transmission-blocking vaccines [31].
In this study, the risk of spread of the challenge strain
of P. falciparum (NF54) into the surrounding area was
thought to be minimal due to treatment of participants
prior to the typical development of gametocytes and the
lack of an appropriate mosquito vector in Nairobi. How-
ever, if the follow-up period prior to treatment were ex-
tended in future studies, particularly in sites with local
transmission of P. falciparum, careful thought should be
given to the potential for natural transmission of the















Figure 4 qPCR results post-challenge for Volunteer 110, Group 2.
Long dashed line = lower limit of detection (i.e., a probability of > 50%
of ≥ 1 positive result among three replicate PCR reactions) for qPCR
assay (5 parasites/mL). Short dashed line = lower limit of quantification
(defined as %CV < 20%) for qPCR assay (20 parasites/mL).Sequencing of parasite at diagnosis
In contrast to CHMI studies conducted at northern cen-
tres, MSP2 genotyping [32] of the parasites collected at
diagnosis was performed to ensure all infections were
clonal (NF54) and resulting from PfSPZ Challenge rather
than natural transmission.
Conclusion In this study, the need to enrol all volun-
teers within one week and confirm this date in advance
in order to coordinate with staff from Sanaria Inc did
limit the time available for screening. If local staff were
trained to thaw and dilute PfSPZ Challenge and load
syringes, then enrolment could be spread over a longer
period, which would be especially useful if there is a dif-
ficulty recruiting appropriate participants. This should
be possible as more of these studies are performed in
centres in malaria-endemic countries.
All participants in this study were successfully in-
fected, however LBIs were notably lower (4,415-106,484
parasites) [13] than those typically seen in mosquito-bite
CHMI studies (240,000-2,835,000 parasites depending
on the CHMI centre) [18]. Recent trials using PfSPZ
Challenge administered intravenously (IV) by direct
venous inoculation (DVI) in 0.5 mL suggest this route of
administration can reliably ensure successful infection in
CHMI trials with lower doses of sporozoites than those
required when administered by other routes [33], and in-
deed 3,200 PfSPZ administered by DVI is now the pre-
ferred dose and route being used currently to assess a
number of novel vaccines (SLH, pers comm). However,
until a vaccine’s efficacy is assessed both in a PfSPZ
Challenge CHMI study and in a field study, it will be un-
known if the PfSPZ Challenge model accurately predicts
vaccine efficacy in a field setting.
Future CHMI studies aiming to examine the dynamics
of NAI or the efficacy of blood stage or transmission-
blocking vaccines should consider treating undiagnosed
volunteers later than C+21. Performing qPCR in real time
to inform treatment decisions and measuring gametocy-
taemia using specific qPCR could also increase the appli-
cations of the CHMI model in Africa [7]. All CHMI sites
in areas of P. falciparum transmission should routinely
perform genotyping on parasites collected at diagnosis to
ensure superadded naturally acquired infection has not
occurred.
Using qPCR in addition to microscopy is important to
distinguish uninfected smear-negative volunteers from
those smear negative volunteers with a parasitaemia
below the threshold of detection by microscopy.
Clinical and laboratory resources
Given the complex and unique nature of CHMI studies,
in particular the need for results to be available in real
time to guide clinical decision making, it was critical
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training in advance of the study. This involved the cre-
ation of 22 clinical and 29 laboratory study-specific
standard operating procedures (SOPs) (Additional file 1:
Tables S6 and S7), weeks of dedicated training sessions
and ‘dry runs’ of the preparation and administration of
PfSPZ Challenge. In order to adhere to internationally
agreed standards [14] and achieve consistency with
northern CHMI centres, significant clinical and labo-
ratory training and support were provided by both na-
tional and international collaborators. Since blood film
positivity was the primary criteria for the start of treat-
ment, microscopy was a critical area of training. All
microscopists passed a two-week refresher-training course
at the KEMRI-affiliated Malaria Diagnostics Centre of
Excellence, Kisumu, Kenya approximately three months
prior to working on study samples. Blood smears were
prepared and interpreted according to a modified ver-
sion of the “Consensus SOP for Malaria Microscopy in
the Context of Clinical Challenge Trials” [13,14]. It was
particularly important in this study to emphasize to the
microscopists, who were used to working in a clinical,
field setting, the importance of avoiding false positive
results.
Conclusion
Support from established CHMI centres and detailed ad-
vanced training was essential for the first Kenyan CHMI
study to take place safely and efficiently.
Feedback
On discharge, all participants were asked to complete an
exit questionnaire providing feedback on their experi-
ence participating in the study. Nineteen of 28 (68%)
participants returned the anonymized questionnaire. Re-
sults were positive (Additional file 1: Table S8) with par-
ticipants reporting good understanding of the study and
discharge procedures.
A written final report will be submitted to the ethical
and regulatory bodies that approved the study and the
results of the study presented to university managers,
local students and interested study participants when all
analyses of study related data is completed.
Conclusion
Whilst this first pilot study in Kenya, it is the start of an
iterative process, which will be informed by these experi-
ences and feedback from volunteers, ethics and regula-
tory bodies and collaborators. In particular, the VIS will
be revised to include more detailed information regard-
ing the issues raised by volunteers. It will also be crucial
to feedback findings of the study to the key stakeholders
in order to help maintain a working relationship for
future CHMI studies.Conclusion
There is a current need to increase the international
capacity for efficacy testing of candidate malaria vac-
cines and allow earlier assessment of novel vaccines and
drugs in the target African populations [7]. The estab-
lishment of the CHMI model in African centres is one
key strategy that could help address these aims [8]. This
study has shown that sporozoite CHMI studies using
PfSPZ Challenge can be safely performed in Kenya in
individuals with varying degrees of prior exposure to
malaria [13].
However, performing CHMI studies in an African
setting presents unique but surmountable challenges. As
the first pilot study performed in Kenya, there were
many learning points, most unique to the African setting
and this paper provides key feedback to aid other
African sites wishing to establish the CHMI model. In
addition, there remain key scientific questions about
PfSPZ Challenge, such as whether protection as assessed
by DVI is comparable to or correlated with protection
assessed by mosquito bite CHMI or natural transmis-
sion, both of which lead to deposition of a portion of the
parasites in the skin. Given the CHMI model has been
shown to be safe and feasible in Kenya, there is hope the
international CHMI and malaria vaccine community will
continue to support the Kenyan site and others to allow
on-going collaborative frameworks to help address these
questions, and to accelerate the development of candi-
date malaria vaccines in malaria-endemic populations.
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